Breakthrough Commercial Stage Awaits By TipRanks
[ad_1]
Over the past six month, shares of Applied Molecular Transport Inc. (AMTI), have declined 58.6%.
As long as it is given a chance by the market, this stock could make a comeback. Therefore, I believe this stock is a good investment. TipRanks has AMTI stock chart charts.
Applied Molecular Transport has its headquarters in San Francisco and is a medical-stage biopharmaceutical development company. This company creates patient-friendly oral treatments for autoimmune disorders as well as metabolic conditions.
Q2 2021
Although the company has not yet sold any treatment, it ended its second quarter 2021 in a slight loss ($23.6M versus $15.4M). The increase in research-and-development expenses and the higher administrative and personnel costs caused this loss.
The company started an equity issuance in April to help cover costs related to clinical trials. Through this, its AMT-101 & AMT-126 products are further evaluated.
AMT-101 addresses ulcerative colitis as well as related inflammation indications. AMT-126 was designed to treat diseases caused by the dysfunction of intestinal epithelium barriers.
AMTI’s cash reserves and investments in short-term assets were $199.5 million as of June 30,
The Market Perspectives
It is working to create innovative treatments for many diseases around the world.
This disease of the intestinal wall can cause annoying symptoms that sometimes severely impact a person’s ability to live a normal life. Although not required every day, patients will in general need of therapy.
This is a growing problem in the world because they have an affinity for modern lifestyles such as cigarette smoking and alcohol consumption.
Relevant top-line information from AMT101 and AMT126 clinical trials will be available starting in the fourth quarter 2021 and continuing through full-year 2022.
These data, if promising, could be more clear evidence of the start of a commercial-stage period for this company.
Wall Street’s Take
Three Wall Street analysts issued price targets for AMTI in the last three months. The average price target of Applied Molecular Transport was $78.33. That implies a potential upside of 200.2%. Based on three Buys, the analyst consensus rating is Strong Buy.
Summary
So far, the stock has been disappointing. But, it could be that the company enters a new stage of commercialization in the next 12 months.
Disclosure: Alberto Abaterusso didn’t hold any position at the time this article was published.
Disclaimer: Information in this article does not necessarily reflect those of TipRanks. TipRanks cannot guarantee the reliability, completeness or accuracy of any information. This article is not intended to be interpreted as an offer or recommendation for the purchase or sale of securities. This article is not intended to provide advice on legal, investment or financial matters. TipRanks, its affiliates, disclaim any liability or responsibility in relation to the content. You are responsible for your actions based upon the articles. TipRanks’ or any affiliates does not endorse this article or make it a recommendation. The past performance of TipRanks or its affiliates is not an indication of future prices, results, or performances.
[ad_2]